• Record $17.2 million quarterly revenue, a 112% increase on Q2 FY25
• Record $18.4 million quarterly Cash Receipts, a 149% increase on Q2 FY25
• $2.5 million positive Q2 cash flow from operating activities

Bioxyne Ltd (ASX: BXN), an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients, has reported a strong Q2 FY26 trading performance. The company achieved record quarterly revenue of $17.2 million, a 21% increase on the previous quarter, and record quarterly cash receipts of $18.4 million, representing a 149% increase on Q2 FY25. The revenue growth was driven by sustained demand for Bioxyne's cannabis portfolio, including flower, oils, vapes, pastilles, and the newly launched Que Medical Inhalation Device, as well as contributions from international expansion and the emerging psychedelics segment. The company also reported positive operating cash flow of $2.5 million for the quarter, benefiting from a research and development tax offset. Bioxyne made significant progress on several operational fronts, including a successful dual listing on the Frankfurt Stock Exchange, an exclusive agreement with Curaleaf International for the distribution of the Que Medical Inhalation Device in Australia, and the release of Australia's first domestically manufactured GMP-compliant MDMA capsules for clinical trials. The company also secured funding from South of Scotland Enterprise to establish a new GMP manufacturing facility in the UK, positioning it as a significant provider of manufacturing and distribution services to the UK medicinal cannabis market. Bioxyne's strong financial and operational performance, coupled with positive regulatory developments in key markets, have the company firmly on track to deliver its FY2026 guidance of $65-75 million in revenue and $11.5-13.5 million in underlying EBITDA.

The company is guiding for FY2026 revenue of $65-75 million and underlying EBITDA of $11.5-13.5 million.

Bioxyne is focused on executing its international expansion plans, including the UK GMP facility fit-out and Central American market entry, improving operational efficiencies, gaining EU GMP certification in Europe, and expanding its medicinal cannabis and psychedelics sales in core markets with local partners.